The utility or lack thereof regarding serum p53 antibody for detecting ulcerative colitis-associated colorectal cancer in the era of immunosuppressive therapy.

Abstract Background: Serum anti-p53 antibodies (Abs) have been considered useful for the early detection of ulcerative colitis-associated colorectal cancer (CAC). However, since the spread of immunosuppressive therapy for ulcerative colitis (UC) treatment in the 2010s, we have experienced a low prevalence of anti-p53 Abs in UC patients. The present study thus examined the utility of serum p53 Abs for detecting CAC in the era of immunosuppressive therapy. Methods: A series of 320 consecutive surgical cases of UC patients between April 2008 and March 2019 were enrolled in this study. Patients with no serum anti-p53 Abs data were excluded. Of the 250 patients analyzed, 219 had no carcinoma or dysplasia (Group non-CAC), and 31 had carcinoma or dysplasia (Group CAC). Serum anti-p53 Abs were detected with an enzyme-linked immunosorbent assay. Immnohistochemical detection was performed in Group CAC. Immunosuppressive therapy included a history of medication with prednisolone >20 mg/day, immunosuppressant drugs, immunomodulator drugs or biologic therapies for UC. Results: Immunosuppressive therapy was performed in 98.1% of Group non-CAC and 80.6% of Group CAC. There were no marked differences in serum anti-p53 Abs positivity between Groups non-CAC and CAC (8.7% vs. 3.2%, p =0.30). p53 staining positivity was noted in 90.3% of Group CAC, and the rate of serum p53 positivity was significantly lower in patients with immunosuppressive therapy than in those without in Group CAC (0.0% vs. 16.7%, p =0.04). Conclusions: The utility of serum p53 Abs for detecting CAC is dubious in the era of immunosuppressive therapy.

Download Full-text

Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer

Disease Markers ◽

10.1155/2019/2721876 ◽

2019 ◽

Vol 2019 ◽

pp. 1-6

Author(s):

Rina Takahashi ◽

Kazuhiro Sakamoto ◽

Kiichi Sugimoto ◽

Shunsuke Motegi ◽

Ryoichi Tsukamoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Surgical Treatment ◽

Tumor Marker ◽

Carbohydrate Antigen ◽

Serum P53 Antibody ◽

P53 Antibodies ◽

Colorectal Cancer Patients ◽

Serum P53 ◽

P53 Antibody

Objective. We examined serum anti-p53 antibodies (S-p53Ab) in colorectal cancer. Specifically, we retrospectively investigated the use of S-p53Ab as a prognostic marker after surgery for colorectal cancer. Materials and Methods. The levels of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) were measured in 160 colorectal cancer patients who underwent surgical treatment. The rate of postoperative change (RPC) in the S-p53Ab titer was calculated as [subsequent antibody titer-lowest titer]/lowest titer. Results. A relationship between recurrence and RPC in the S-p53Ab titer was not observed in patients who tested negative for S-p53Ab preoperatively. In addition, no patients, who tested negative for S-p53Ab preoperatively, tested positive for S-p53Ab at the follow-up after surgery. Of the patients who tested positive for S-p53Ab preoperatively, those recurrences had a significantly higher RPC compared with those who did not (p<0.001). Conclusions. Although S-p53Ab is not a significant tumor marker in patients who test negative preoperatively, increases in the S-p53Ab titer should be continuously monitored and measured in patients who are positive for this antibody preoperatively, regardless of whether they later test negative.

Download Full-text

IS A FAMILY HISTORY OF COLORECTAL CANCER AS RELEVANT FOR ULCERATIVE COLITIS PATIENTS AS FOR COTTON-TOP TAMARINS?

Inflammatory Bowel Diseases ◽

10.1097/00054725-199908000-00017 ◽

1999 ◽

Vol 5 (3) ◽

pp. 238

Author(s):

Anders Ekbom

Keyword(s):

Colorectal Cancer ◽

Ulcerative Colitis ◽

Family History ◽

History Of

Download Full-text

Ulcerative Colitis and Sweet’s Syndrome: A Case Report and Review of the Literature

Canadian Journal of Gastroenterology ◽

10.1155/2008/960585 ◽

2008 ◽

Vol 22 (3) ◽

pp. 296-298 ◽

Cited By ~ 22

Author(s):

Massud Ali ◽

Donald R Duerksen

Keyword(s):

Ulcerative Colitis ◽

Immunosuppressive Therapy ◽

Neutrophilic Dermatosis ◽

Sweet’S Syndrome ◽

Review Of The Literature ◽

Neutrophilic Infiltration ◽

Drug Induced ◽

Sweet's Syndrome ◽

History Of ◽

Inflammatory Bowel

A 47-year-old man with a history of ulcerative colitis on prednisone and azathioprine was admitted to the hospital with a four-day history of fever, skin rash, arthralgias and leukocytosis. A skin biopsy demonstrated neutrophilic infiltration of the dermis that was consistent with Sweet’s syndrome. He improved after several days with an increase in his prednisone and azathioprine. Sweet’s syndrome is a rare cutaneous manifestation of inflammatory bowel disease, with approximately 40 cases reported in the literature. In a previously reported case of a patient with ulcerative colitis-associated Sweet’s syndrome who was on azathioprine at the time of the skin eruption, the azathioprine was stopped, raising the possibility of drug-induced Sweet’s syndrome. In the present case, the azathioprine was actually increased with complete resolution of the skin manifestations. This would support the theory that immunosuppressive therapy is the mainstay of therapy for this condition. In conclusion, Sweet’s syndrome is a neutrophilic dermatosis that is rarely associated with ulcerative colitis. It may occur while on immunosuppressive therapy and responds to an intensification of immunosuppression.

Download Full-text